バイオシミラーインターロイキンの世界市場レポート 2024年

バイオシミラーインターロイキンの市場規模は、今後数年間で急激に成長すると予想されます。 2028年には40.0%の年間複合成長率（CAGR）で207億9,000万米ドルに成長すると予想されます。予測期間の予想される成長は、いくつかの重要な要因により予想されます。これらには、バイオシミラーインターロイキンによる治療を求める患者数の拡大、医療サービスの利用を容易にするアクセスの改善、個々のニーズに合わせて治療を調整する個別化医療に対する需要の高まり、低侵襲医療処置に対する嗜好の増加などが含まれます。

乾癬や関節リウマチなどの自己免疫疾患の予想される増加により、次の予測期間にインターロイキンバイオシミラー市場の成長が促進される見込みです。これらの状態では、免疫細胞が健康な抗体と潜在的に有害な抗体を区別するのに苦労しています。抗インターロイキン抗体を含む生物学的製剤は、細胞を調節し、その増殖、活性化、移動に影響を与えることにより、臨床上の重要な利点を実証しています。ジョンズ・ホプキンス大学の2021年の報告書では、自己免疫疾患は米国人口の約3％に影響を及ぼし、およそ1,000万人が影響を受けていると推定しました。この自己免疫疾患の有病率の拡大により、バイオシミラーインターロイキンの需要が高まり、市場の成長が促進されると予想されます。

関節炎の有病率の増加がバイオシミラーインターロイキン市場の成長を促進すると予測されています。関節の不快感や炎症を特徴とする関節炎には、1つまたは複数の関節に影響を及ぼす症状が含まれます。インターロイキンを含むバイオシミラーは、関節リウマチ（RA）や乾癬性関節炎などを含む、さまざまな炎症性疾患や自己免疫疾患の管理において極めて重要です。 2021年10月のアメリカ疾病管理予防センターの予測によると、2040年までに、予測成人人口の約25.9％に当たる18歳以上の約7,840万人が医師による関節炎の診断を受けると予想されており、関節炎の診断を受ける人は増加傾向にあると予想されています。その結果、関節炎の有病率がエスカレートすることで、バイオシミラーインターロイキン市場の成長が促進されることになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のバイオシミラーインターロイキン市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のバイオシミラーインターロイキンの市場規模実績と成長、2018～2023年
• 世界のバイオシミラーインターロイキン市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のバイオシミラーインターロイキン市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• IL-17
• IL-23
• IL-1
• IL-5
• IL-6
• 世界のバイオシミラーインターロイキン市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 乾癬
• 乾癬性関節炎
• 関節リウマチ
• 喘息
• 炎症性腸疾患（IBD）
• その他
• 世界のバイオシミラーインターロイキン市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• オンライン薬局
• 小売薬局
• クリニック
• 研究機関

第7章 地域と国の分析

• 世界のバイオシミラーインターロイキン市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のバイオシミラーインターロイキン市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラーインターロイキン市場の競合情勢
• バイオシミラーインターロイキン市場の企業プロファイル
  • Mabpharm Limited
  • Gedeon Richter plc
  • Bio-Thera Solutions Ltd.
  • Sorrento Therapeutics
  • Sunshine Guojian Pharmaceutical

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

Biosimilar interleukins refer to proteins produced by the body's white blood cells, known as leukocytes. These interleukins play a crucial role in regulating immune responses. Laboratory-generated interleukins are utilized as biological response modifiers to fortify the immune system, particularly in cancer treatment.

Various types of biosimilar interleukins include IL-17, IL-23, IL-1, IL-5, IL-6, among others. For instance, Interleukin 17 belongs to the pro-inflammatory cystine knot cytokine family and is produced by a specific subset of T helper cells, known as T helper 17 cells, in response to IL-23 stimulation. These biosimilar interleukins find diverse applications in treating conditions such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and other immune-related disorders. They are made available through various distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, clinics, as well as research institutes, catering to different healthcare settings and patient needs.

The biosimilar interleukins market research report is one of a series of new reports from The Business Research Company that provides biosimilar interleukins market statistics, including biosimilar interleukins industry global market size, regional shares, competitors with a biosimilar interleukins market share, detailed biosimilar interleukins market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar interleukins industry. The biosimilar interleukins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 39.0%. The growth observed in the historical period can be attributed to several factors. These include the escalating prevalence of autoimmune diseases requiring targeted treatments with biosimilar interleukins, a growing awareness regarding the efficacy and benefits of these treatments among healthcare providers and patients, increasing governmental support for the development and utilization of biosimilars, expansion in the biosimilar market offering more options, and a rising demand from patients seeking accessible and effective treatment options through biosimilar medications. These factors collectively contributed to the growth and adoption of biosimilar interleukins during this period.

The biosimilar interleukins market size is expected to see exponentially grown in the next few years. It will grow to $20.79 billion in 2028 at a compound annual growth rate (CAGR) of 40.0%. Anticipated growth in the forecast period is expected due to several key factors. These include the expansion of the patient population seeking treatment with biosimilar interleukins, improved accessibility to healthcare services facilitating their use, a growing demand for personalized medicine tailoring treatments to individual needs, and an increased preference for minimally invasive medical procedures.

The anticipated rise in autoimmune diseases like psoriasis and rheumatoid arthritis is poised to propel growth within the interleukin biosimilars market in the upcoming forecast period. These conditions involve immune cells struggling to differentiate between healthy and potentially harmful antibodies. Biologic drugs, including anti-interleukin antibodies, have demonstrated significant clinical benefits by regulating cells and influencing their proliferation, activation, and migration. A report from Johns Hopkins University in 2021 estimated that autoimmune diseases impacted around 3% of the United States population, affecting roughly 10 million individuals. This escalating prevalence of autoimmune diseases is expected to fuel the demand for biosimilar interleukins and drive market growth.

The increasing prevalence of arthritis is forecasted to drive the growth of the biosimilar interleukins market. Arthritis, characterized by joint discomfort or inflammation, encompasses conditions affecting one or multiple joints. Biosimilars containing interleukins are pivotal in managing various inflammatory and autoimmune conditions, including rheumatoid arthritis (RA), psoriatic arthritis, and others. As per the Centers for Disease Control and Prevention's projections in October 2021, it is anticipated that by 2040, approximately 78.4 million adults aged 18 and older, roughly 25.9% of the projected adult population, will receive a physician's diagnosis of arthritis, marking an increase from 63 million in 2020. Consequently, the escalating prevalence of arthritis is set to propel the growth of the biosimilar interleukins market.

Key players in the biosimilar interleukins market are introducing innovative products like Tofidence (tocilizumab-bavi) to bolster their profitability in the market. Tofidence, a monoclonal antibody targeting and binding to interleukin-6 receptors, serves in treating various inflammatory autoimmune disorders. In September 2023, Biogen, a US-based biotechnology company, received FDA approval for Tofidence (tocilizumab-bavi) as the initial biosimilar to Genentech's Actemra (tocilizumab). Administered via intravenous infusion, Tofidence has gained approval for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis, marking a strategic move to enhance their market presence and profitability.

Equillium, a biotech company headquartered in the United States, finalized the acquisition of Bioniz Therapeutics, Inc. in February 2022 for a substantial sum of $329 million. This acquisition significantly expands Equillium's array of innovative immunomodulatory drug candidates by providing access to three therapeutics and additional assets in the discovery phase. Bioniz Therapeutics Inc., also based in the United States, is a biotechnology company specializing in this field. This strategic acquisition is poised to strengthen Equillium's portfolio and accelerate its efforts in developing cutting-edge treatments in the realm of immunomodulation.

Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter PLC, Bio-Thera Solutions Ltd., Sorrento Therapeutics, Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Biogen Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Mylan N.V.

North America was the largest region in the biosimilar interleukins market in 2023. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar interleukins market consists of sales of mabPharm, gedeonrichter, and bio-thera solutions. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilar Interleukins Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar interleukins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar interleukins? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilar interleukins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: IL-17; IL-23; IL-1; IL-5; IL-6
• 2) By Application: Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Asthma; Inflammatory Bowel Disease (IBD); Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Clinics; Research Institutes
• Companies Mentioned: Mabpharm Limitied; Gedeon Richter plc; Bio-Thera Solutions Ltd.; Sorrento Therapeutics; Sunshine Guojian Pharmaceutical
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilar Interleukins Market Characteristics

3. Biosimilar Interleukins Market Trends And Strategies

4. Biosimilar Interleukins Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Biosimilar Interleukins Market Size and Growth

• 5.1. Global Biosimilar Interleukins Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Biosimilar Interleukins Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Biosimilar Interleukins Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biosimilar Interleukins Market Segmentation

• 6.1. Global Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• IL-17
• IL-23
• IL-1
• IL-5
• IL-6
• 6.2. Global Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Asthma
• Inflammatory Bowel Disease (IBD)
• Other Applications
• 6.3. Global Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Clinics
• Research Institutes

7. Biosimilar Interleukins Market Regional And Country Analysis

• 7.1. Global Biosimilar Interleukins Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Biosimilar Interleukins Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biosimilar Interleukins Market

• 8.1. Asia-Pacific Biosimilar Interleukins Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biosimilar Interleukins Market

• 9.1. China Biosimilar Interleukins Market Overview
• 9.2. China Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biosimilar Interleukins Market

• 10.1. India Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biosimilar Interleukins Market

• 11.1. Japan Biosimilar Interleukins Market Overview
• 11.2. Japan Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biosimilar Interleukins Market

• 12.1. Australia Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biosimilar Interleukins Market

• 13.1. Indonesia Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biosimilar Interleukins Market

• 14.1. South Korea Biosimilar Interleukins Market Overview
• 14.2. South Korea Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biosimilar Interleukins Market

• 15.1. Western Europe Biosimilar Interleukins Market Overview
• 15.2. Western Europe Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biosimilar Interleukins Market

• 16.1. UK Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biosimilar Interleukins Market

• 17.1. Germany Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biosimilar Interleukins Market

• 18.1. France Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biosimilar Interleukins Market

• 19.1. Italy Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biosimilar Interleukins Market

• 20.1. Spain Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biosimilar Interleukins Market

• 21.1. Eastern Europe Biosimilar Interleukins Market Overview
• 21.2. Eastern Europe Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biosimilar Interleukins Market

• 22.1. Russia Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biosimilar Interleukins Market

• 23.1. North America Biosimilar Interleukins Market Overview
• 23.2. North America Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biosimilar Interleukins Market

• 24.1. USA Biosimilar Interleukins Market Overview
• 24.2. USA Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biosimilar Interleukins Market

• 25.1. Canada Biosimilar Interleukins Market Overview
• 25.2. Canada Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biosimilar Interleukins Market

• 26.1. South America Biosimilar Interleukins Market Overview
• 26.2. South America Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biosimilar Interleukins Market

• 27.1. Brazil Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biosimilar Interleukins Market

• 28.1. Middle East Biosimilar Interleukins Market Overview
• 28.2. Middle East Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biosimilar Interleukins Market

• 29.1. Africa Biosimilar Interleukins Market Overview
• 29.2. Africa Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Biosimilar Interleukins Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Biosimilar Interleukins Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biosimilar Interleukins Market Competitive Landscape And Company Profiles

• 30.1. Biosimilar Interleukins Market Competitive Landscape
• 30.2. Biosimilar Interleukins Market Company Profiles
  • 30.2.1. Mabpharm Limited
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Gedeon Richter plc
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bio-Thera Solutions Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sorrento Therapeutics
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sunshine Guojian Pharmaceutical
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Biosimilar Interleukins Market Competitive Benchmarking

32. Global Biosimilar Interleukins Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Biosimilar Interleukins Market

34. Biosimilar Interleukins Market Future Outlook and Potential Analysis

• 34.1 Biosimilar Interleukins Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Biosimilar Interleukins Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Biosimilar Interleukins Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer